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Abstract 
	
 
Gangliosides are membrane glycosphingolipids which are widely distributed within cells of the 
central nervous system and play a pivotal role in cell repair and injury. Gangliosides exist in 
equilibrium within the cell; however, this equilibrium shifts in response to stress such that the 
complex ganglioside GM1 is degraded to simpler species GM2 and GM3. Complex gangliosides 
are linked to an upregulation of neuroprotective signaling while simple species have been 
associated with neurodegeneration and cell death. In this study, we therefore sought to perturb the 
gangliosides homeostasis using Ambroxol; a ganglioside modifying agent that has been shown to 
perturb enzymes in the ganglioside degradation pathway, in order to determine if Ambroxol has 
any effects on neuronal ganglioside expression profiles, and to compare the neuroprotective 
potential of Ambroxol to exogenous GM1 treatment in neurons undergoing oxygen glucose 
deprivation (OGD). Primary embryonic (E18) rat cortical neurons were cultured, and at DIV (days 
in vitro) 10 treated with different concentrations of Ambroxol for up to 24 h. GM1 and GM3 
gangliosides were visualized using immunocytochemistry. GM1, GM2 and GM3 species were 
quantified using electrospray ionization mass spectrometry (ESI-MS). Immunofluorescence 
demonstrated that GM1 significantly increased 6 h following treatment with Ambroxol. ESI-MS 
data revealed that GM1 increased at 6 h and 24 h post treatment. To test the neuroprotective 
potential of Ambroxol, neurons were pre-treated with either Ambroxol for 6 h or exogenous GM1 
for 24 h prior to 1 h oxygen glucose deprivation (OGD), and re-perfused for 6 h and 24 h. Cell 
viability was assessed using propidium iodide (PI) staining. Compared to untreated neurons and 
to neurons only exposed to OGD, neurons treated with Ambroxol and exposed to OGD showed 
no increase in cell death after OGD/R injury. Exogenous GM1 pretreatment conferred 
neuroprotection and enhanced endogenous GM1 levels. These preliminary results suggest that 
Ambroxol increases GM1levels in neurons and may confer a neuroprotective effect. All in all, 
modulating ganglioside levels by ganglioside enzyme modifiers may uncover a new lipid based 
therapeutic approach to protect neurons and promote their survival following stress or injury. 
 
Keywords: ganglioside, primary cortical neurons, ESI-MS, OGD, Ambroxol 
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Section 1: INTRODUCTION 
	 2	
1.1 Brain Vulnerability 
	
     As we age, our brains become more prone to disease and injury resulting in neurodegeneration. 
However, neuroanatomical areas within the brain differ in their sensitivity to neurodegeneration. 
For example, in Alzheimer’s disease (AD), the most affected brain regions are the hippocampus, 
amygdala, neocortex, and basal nucleus (Braak & Braak, 1991; Wenk, 2003), while in Parkinson’s 
disease (PD) there is a loss of dopaminergic neurons in the substantia nigra (Damier, Hirsch, Agid, 
& Graybiel, 1999; Schneider, 2018). Similarly, neuronal vulnerability after a stroke injury is 
dependent on the anatomical location of the insult and severity of ischemic damage. For example, 
hippocampal CA1 pyramidal neurons have been shown to be more susceptible to degeneration  
than neurons of the dentate gyrus (Schmidt-Kastner & Freund, 1991; Woodruff et al., 2011), while 
the corpus callosum has demonstrated more severe demyelination in response to toxicity compared 
to other white matter tracts (Goldberg, Clarner, Beyer, & Kipp, 2015). In addition, neuronal 
vulnerability varies according to the kind of the ischemic damage. For example, the caudate 
nucleus is more vulnerable to ischemic stress under circulatory arrest while the hippocampus is 
more vulnerable to ischemic stress under low flow bypass (Ishibashi et al., 2010).  This selective 
vulnerability of different brain regions to toxic insults could be explained by the molecular 
composition of the plasma membrane since it is the first point of contact with the external 
environment.  
 
1.2 Cell Membrane 
	
     The plasma membrane is a heterogeneous structure which is composed of a phospholipid 
bilayer, protein, cholesterol, and sugar molecules (Lingwood & Simons, 2010). It has a fluid 
mosaic structure that can alter its lipid composition in response to external stimuli (Bormann & 
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Likens, 2018). The plasma membrane contains specialized subdomains called lipid rafts which are 
enriched in cholesterol, proteins, and sphingolipids (Pike, 2003). These organized structures play 
a critical role in protein sorting, cell adhesion, and cell signaling (Simons & Toomre, 2000; 
Sonnino, Mauri, Chigorno, & Prinetti, 2006). One of the primary components of lipid rafts are a 
group of membrane lipids called gangliosides (Sonnino et al., 2006).  
 
1.3 Ganglioside Structure 
	
     Gangliosides are mono- or poly-sialylated glycosphingolipids located primarily in the outer 
layer of the plasma membranes. They have an amphiphilic character due to a hydrophobic 
ceramide moiety embedded within the cell membrane, and a series of hydrophilic sugar molecules 
that protrude from the cell surface (Sonnino et al., 2006). Gangliosides are highly diverse structures 
which vary based on differences in the ceramide moiety and the oligosaccharide chain. The 
oligosaccharide chain is composed of a combination of glucose, galactose, and N-
acetylgalctosamine, along with a sialic acid residue that is attached to the galactose molecule 
(Schnaar, Gerardy-Schahn, & Hildebrandt, 2014). The ceramide moiety is composed of a fatty 
acid connected to a sphingosine base of variable length by an amide linkage. Gangliosides are 
classified by the length of the carbon chain located within the sphingosine moiety. GM1d18:1 is 
the predominant species, containing 18 carbon atoms in its sphingosine base, with GM1d20:1, 
containing 20 carbon atoms, being the second most common species (Rosenberg & Stern, 1966) 
(Figure 1). Moreover, gangliosides are further classified into asialo, a-, b- and c-series based on 
the number of sialic acid residues linked to the inner galactose molecule. The letter G stands for 
gangliosides, M/D/T/Q(mono-/di-/tri-/tetra) refer to the number of sialic acid residues, with a 
number 1, 2 or 3 (GM1, GM2, GM3) according to their migration using thin layer chromatography 
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(Yu, Tsai, Ariga, & Yanagisawa, 2011). 
 
1.4 Ganglioside Synthesis Vs Degradation 
	
     Depending on the cell type and the stage of development, ganglioside composition can be 
variable within cells. The distribution of each ganglioside species is enzymatically regulated 
through tight control of biosynthetic and degradative pathways (Sandhoff & Harzer, 2013). 
     Gangliosides are synthesized initially in the endoplasmic reticulum (ER) from the lipid 
precursor ceramide (Cer) which is embedded in ER membranes (Figure 2). The synthesis continues 
by glycosyltransferases and sialyltransferases in the golgi complex and trans-golgi network 
(TGN), adding sugar and sialic acid residues. Glucosylceramide (GlcCer) is formed in the golgi 
cytosolic membrane via glucosyltransferase (GlcT), and transferred to the golgi luminal side to 
form lactosylceramide (LacCer) via galactosyl transferase I (Gal-T1). GM3, the only precursor of 
a, b and c-series gangliosides, is synthesized at the luminal surface of the golgi complex after 
sialylation of LacCer by sialyltransferase I (Sial-T1). GD3 and GT3 are formed by addition of 
sialic acids to GM3 mediated by sialyltransferase II (Sial-T2) and sialyltransferase III (Sial-T3) 
respectively. GM3, GD3 and GT3 are the precursors of a, b and c-series gangliosides respectively. 
Complex gangliosides are synthesized later by various glycosyltransferases such as N-
acetylgalactosaminyltransferase (GalNAcT), galctosyltransferase II (Gal-T2), sialyltransferase IV 
(Sial-T4) and sialyltransferase V (Sial-T5). These complex gangliosides are then transported to 
cell membranes through secretory pathways (Figure 2) (Kolter, Proia, & Sandhoff, 2002; Sandhoff 
& Harzer, 2013; Yu et al., 2011). 
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Figure 1. Ganglioside structure.	Gangliosides are composed of a ceramide moiety containing 
fatty acid and variable carbon length sphingosine base (mainly 18 and 20 carbons), and an 
oligosaccharide chain attached to one or more sialic acid residues. Figure modified from 
Weishaupt et al., 2015.	
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Figure 2. Ganglioside synthesis pathway. Gangliosides are synthesized from the lipid precursor 
ceramide which is generated in the ER, and their synthesis is continued in Golgi complex via 
glycosyltransferases and sialyltransferases, adding sugar and sialic acid residues respectively. 
GalNAc-T: Nacetylgalactosaminyltransferase or GM2/ GD2/ GT2 synthase, GalT-1: 
galactosyltranferase I, GalT-2: galactosyltranferase II or GM1 synthase, Glc-T: 
glucosyltransferase, Sial-T1: sialyltransferase I or GM3 synthase, Sial-T2: sialyltransferase II or 
GD3 synthase, Sial-T3: sialyltransferase III or GT3 synthase, Sial-T4: sialyltransferase IV or 
GD1a synthase, Sial-T5: sialyltransferase V or GT1a synthase. Modified from (Konrad Sandhoff 
& Kolter, 2003). 
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     The degradation of gangliosides takes place in acidic structures of the cell called endosomes 
and lysosomes in a stepwise manner, catalyzed by the glycosidases that sequentially split off the 
carbohydrate residues in the presence of membrane perturbing activator proteins. Firstly, GT1b 
and GQ1b, complex gangliosides that contain more than one sialic acid, are degraded to GM1 at 
the cell membrane by membrane-bound sialidases. Within the lysosome, GM1 is hydrolyzed to 
GM2 by ß-galactosidase in the presence of the GM2 activator protein (GM2-AP) or saposin B 
(SAP-B) and bis(monoacylglycero)phosphate (BMP). GM2 is cleaved to GM3 by 
hexoseaminidase (HexA) and in the presence of the membrane perturbing protein including GM2-
AP. Then, sialidases are stimulated by SAP-B to remove sialic acid from GM3 to form lacCer, and 
eventually Cer is produced by the catalytic galactosidase and glucocerebrosiadse (GCase) (Figure 
3) (Kolter & Sandhoff, 2006; Konrad Sandhoff & Kolter, 2003; Wilkening, Linke, Uhlhorn-
Dierks, & Sandhoff, 2000).  
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Figure 3.Ganglioside degradation pathway. Gangliosides degradation takes place in the acidic 
compartments endosome and the lysosome in a stepwise manner, catalyzed by the glycosidases 
and the sialidases that sequentially split off the carbohydrate and sialic acid residues. Gal: 
galactosidase, GCase: glucocerebrosidase. Modified from (Kolter, 2012). 
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1.5 Ganglioside d18:1 and d20:1 Sphingosine Moieties in the CNS  
	
      Sphingosine moieties of gangliosides have a distinct neuroanatomical distribution within the 
brain during health and injury (Caughlin et al., 2017a; Weishaupt, Caughlin, Yeung, & Whitehead, 
2015; Whitehead et al., 2011). For example, a high level of GM1 d18:1 has been observed in the 
deep layers of healthy rat cerebral cortex whereas GM1 d20:1 was more abundant in superficial 
layers (Weishaupt et al., 2015). Similarly, the d18:1 and d20:1 species of GM1 have also shown a 
unique distribution pattern among the various layers of the rat hippocampus (Caughlin et al., 
2017b; Caughlin et al., 2018; Sugiura et al., 2008). Furthermore, the d18:1 and d20:1 species of 
gangliosides have shown unique shifts in their distribution profiles in response to stroke injuries 
in a number of rodent models. For instance, Caughlin et al. found that the d18:1 and d20:1 species 
of A-series gangliosides responded differently to neurodegenerative stroke injuries of varying 
severity in the rat brain, with the less abundant d20:1 species often showing a more severe 
perturbation compared to the more abundant d18:1 species. (Caughlin et al., 2015). Also, 
Whitehead et al. demonstrated the unique expression of d18:1 and d20:1 species in mice brain 
hippocampi following MCAO reperfusion, in which d20:1 of GM1, GD1 and GT1b gangliosides 
were expressed strongly in the dentate gyrus whereas d18:1 was expressed in the other areas of the 
hippocampus such as stratum radiatum and molecular layer (Whitehead et al., 2011).  
     The abundance and distribution of gangliosides with different sphingosine moieties changes 
during aging. GM1 d20:1 showed an increase in adult rat brains in comparison to embryonic 
cortical cultures (Human, Palestini, Sonnino, & Tettamanti, 1991; Park, Wang, Pittock, Lajoie, & 
Whitehead, 2016). Moreover, an aging study conducted in our lab showed that the d20:1/d18:1 
ratio of GM2 and GM3 was high during early development across the brain of Fischer rats while 
d20:1 species of GM1 and GD1 were  low (Caughlin et al., 2017a). This pattern shifted during 
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adulthood such that the d20:1/d18:1 ratio dropped for gangliosides GM2 and GM3 in most brain 
regions and increased in an age-dependent manner for gangliosides GM1 and GD1. A follow up 
study showed that the shift in the d20:1/d18:1 ratio between early development and adulthood in  
Fischer rats was highly brain region specific, but was generally caused by a depletion of d20:1 
species for simple gangliosides GM2 and GM3, and an increase in d20:1 species for complex 
gangliosides GM1 and GD1 (Caughlin et al., 2018). Another study using developing cerebellar 
neurons showed significant changes in d18:1 and d20:1 long chain sphingosine bases during 
development (Valsecchi, Chigorno, Nicolini, & Sonnino, 1996). All of these findings suggest the 
distinct and crucial role of these ganglioside species in neuronal processes. 
 
1.6 Gangliosides in the Central Nervous System 
	
     Gangliosides exist in all mammalian cells, but are widely distributed in the cells of the central 
nervous system (Kolter, 2012; Kracun et al., 1992; Ledeen & Yu, 1982). They form 10%-12% of 
the lipid component of neuronal membranes and are mainly found in grey matter (Kolter, 2012). 
Gangliosides constitute 75% of the conjugated sialic acid in the brain (Schnaar et al., 2014). The 
most common gangliosides in the adult human brain are GM1, GD1a, GD1b, GT1b (Kolter et al., 
2002). Gangliosides perform their regulatory functions either by interacting with adjacent proteins 
on the same cell membrane (cis), or by binding with a glycoprotein on the neighboring cells or in 
the extra cellular space (trans) (Schnaar, 2016). 
     Strong evidence supports the regulatory role of gangliosides in neuronal development. During 
development, gangliosides shift from the simple forms GM3 and GD3 predominant in embryonic 
life to the more complex forms GM1, GD1a, GD1b, and GT1b predominant in later life 
(Ngamukote, Yanagisawa, Ariga, Ando, & Yu, 2007). Gangliosides continue to shift in their 
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balance throughout aging whereby GM1a and GD1a decrease with concomitant increases in GD1b 
and GT1b (Caughlin et al., 2017b; Svennerholm et al., 1989). Svennerholm et al. found a dramatic 
increase in GM1 and GD1a in the frontal lobes of  human fetuses at term; a time that coincides 
with axonal outgrowth, synaptogenesis and dendrite arborization (Svennerholm et al., 1989). 
Another study showed that GM1 was involved in glia-neuronal contacts during neuroblast 
migration, and also found that GM3 was localized in areas where cell proliferation occurs 
(Stojiljković et al., 1996). These findings are indicatives of the pivotal role of each species at 
various stages of development. 
     Knocking out of ganglioside synthase genes results in a range of structural and functional 
disturbances such as neuronal degeneration, demyelination, axonal deterioration, motor and 
sensory dysfunction, and altered neuronal development (Allende & Proia, 2014; Ribeiro-Resende 
et al., 2014; Schnaar et al., 2014). For example, GM3 synthase knock out mice showed motor 
hyperactivity and behavioral disturbances (Niimi et al., 2011). A defect in  GM3 synthase gene 
resulted in the absence of GM3 and the other complex gangliosides in the human brain; this 
deficiency was associated with seizures, blindness and neurological abnormalities (Simpson et al., 
2004). Mice producing only GM3 and lacking complex gangliosides suffered abnormalities in 
spatial learning and memory, motor dysfunction and weight loss (Tajima et al., 2009). 
     Gangliosides are involved in signal transduction and ion channel modulation which are critical 
in neuronal excitability and synaptic transmission (Fernandes De Lima, Wiedemann, Klottig, 
Rahmann, & Hanke, 1997; Ledeen & Wu, 2002; Weber, Rudel, Aulkemeyer, & Brinkmeier, 
2000). GM1 has been involved in maintaining conduction velocity and excitability by regulating 
Na+   channels. Weber et al. reported that anti GM1 antibodies blocked sodium channels in neurons, 
and resulted in a delay in axonal conduction velocity (Weber et al., 2000). Moreover, GM1 and 
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GD1a are implicated in stabilizing neuronal Ca2+ level (Wang, Tsui, & Yang, 1999; Xie, Wu, Lu, 
& Ledeen, 2002). GM1 regulates Ca2+ flux through nuclear and cellular membranes by activating 
Na+/Ca 2+ exchange and by modulating non-voltage gated Na+ channel (Ledeen & Wu, 2002). All 
in all, these studies indicate that gangliosides are not only important for stabilizing the neuronal 
membrane and protecting the cellular appearance, but are also involved in many critical neuronal 
processes. 
 
1.7 GM1 Ganglioside 
	
     GM1 is a structurally complex ganglioside that is expressed ubiquitously in the adult healthy 
brain. It constitutes, with the other main complex gangliosides, up to 90% of ganglioside content 
in the adult brain (Kolter et al., 2002; Palmano, Rowan, Guillermo, Guan, & McJarrow, 2015). It 
has been reported that GM1 is expressed abundantly in the healthy rodent brain as detected by 
matrix assisted laser desorption ionization mass spectrometry (MALDI-MS) imaging (Whitehead 
et al., 2011).  
     Several studies have demonstrated that GM1 is involved in neuronal survival, protection and 
repair after injury including stroke, spinal cord injury, PD, and Huntington’s disease (HD) (Geisler, 
Coleman, Grieco, Poonian, & Group, 2001; Maglione et al., 2010; Schneider et al., 2013). GM1 
provided promising results following brain ischemia in preclinical studies. One study showed that 
intraperitoneal injection of GM1 minimized edema and protected against blood flow disturbance 
following focal cerebral ischemia in rats (Koga et al., 1990). Additionally, GM1 protected against 
hypoxic ischemic rat brain injury by preventing myelin sheath damage through stabilization of the 
interactions of neurofascin 155 protein with other components of lipid rafts (Zhang, Huang, Zhao, 
Tang, & Wang, 2011). Another study reported that GM1 treatment minimized stroke-induced 
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infarct size following focal cerebral ischemia in rats by modulating the excitatory N-Methyl-D-
Aspartate glutamate receptor  (Liu et al., 2005). GM1 treatment also protected against cerebral 
ischemia in fetal sheep where it decreased the histological damage in the cortex and hippocampus, 
reduced seizure duration, and minimized edema (Tan, Williams, Gunn, Mallard & Gluckman, 
1993). A recent study in our lab showed that GM1 pretreatment protected against glutamate 
induced cell death in primary cortical embryonic rat neurons. In the same study, GM1 increased 
transiently following glutamate exposure only in viable neurons, suggesting that GM1 expression 
increased as a neuroprotective mechanism after glutamate-induced stress (Park et al., 2016). 
However, GM1 treatment did not show an improvement in stroke patients where patients 
developed allergic reactions or Guillain-Barré syndrome (Candelise & Ciccone, 2002). 
     GM1 has been linked to neuronal survival in PD models. Experimentally, GM1 treatment 
provided promising results in monkey models of PD induced through administration of 1-methyl-
4phenyl-1,2,3,6-tetrahydropyridine (MPTP), in which GM1 increased dopaminergic innervation 
in the striatum of the Parkinsonian monkeys and was associated with functional improvement 
including akinesia, rigidity, and bradykinesia (Pope-Coleman, Tinker, & Schneider, 2000). In 
clinical trials, PD subjects who received GM1 treatment showed improvement in  motor 
dysfunction, and had a delay in overall disease progression (Schneider et al., 2013). GM1 treatment 
has also showed protection of motor, sensory, and  autonomic functions in patients with spinal 
cord injuries (SCI) (Geisler et al., 2001). Another study showed the involvement of GM1 in 
Huntington’s disease (HD). Maglione et al, found that GM1 level decreased in HD fibroblast, and 
this reduction resulted in an increase in apoptosis. However, GM1 treatment led to a recovery of 
GM1 levels in HD cells and enhanced their survival, suggesting that GM1 decrease could be one 
of the mechanisms underlying HD pathology (Maglione et al., 2010). Overall, the above mentioned 
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studies point to the positive effect of GM1 in neurodegenerative disorders. 
     Different theories have been proposed to explain the mechanisms by which GM1 performs its 
neuroprotective roles within the cell. It is believed that the neuroprotective potential of GM1 is 
conducted through either activation or mimicking the action of neurotrophic factors. One of these 
theories is through activation of mitogen activated protein kinase (MAPK) and cAMP response 
element binding (CREB) protein, a key element in cell survival. Choi et al found that injection of 
GM1 in the vitreous body following optic nerve axotomy activated MAPK and CREB pathway, 
and this enhanced retinal ganglion cell survival (Choi, Kim, & Joo, 2003). Another study 
conducted in a glioma cell line expressing trkA receptors which have a high affinity to nerve 
growth factor (NGF), reported that GM1 potentiates (NGF) mediated activation of tyrosine 
phosphorylation of trkA (Rabin & Mocchetti, 1995).  
 
1.8 GM2 Ganglioside 
	
     GM2 is, structurally, one of the simple gangliosides, and is associated with several functions 
within the CNS. GM2 is expressed only at very low levels in healthy rodent brains; however, this 
ganglioside has been observed to increase transiently within the stroke region in several rodent 
models of ischemic injury (Caughlin et al., 2015; Kolter et al., 2002; Whitehead et al., 2011). GM2 
has also been observed to increase transiently at the site of injury in a mouse model of traumatic 
brain injury (Woods et al., 2013). The timing of increased GM2 after stroke and traumatic brain 
injury (TBI) suggests that this transient increase may be linked to important neuro-inflammatory 
mechanisms underlying brain injury. 
     GM2 has also been found to accumulate in enzymatic disorders (Kodama et al., 2011; Zervas, 
Somers, Thrall, & Walkley, 2001). A study conducted in both Tay Sachs and Sandhoff disease 
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patients and Sandhoff disease mouse model has shown that GM2 accumulated in mice brains and 
was elevated in patients plasma (Kodama et al., 2011). GM2 is also involved in the pathogenic 
cascade in Niemman Pick disease, a disorder in which there is an accumulation of cholesterol and 
sphingolipids including ganglioside within the brain (Zervas et al., 2001). This may indicate that 
GM2 could be a potential marker of these disorders.  
     Moreover, studies have shown that GM2 is implicated in AD pathology. Yang et al. found that 
there was an accumulation of GM2 in auto-phagosomes and autolysosomes in the brains of mouse 
models of AD (Yang et al., 2014). Another study in AD patient autopsy brains showed that GM2 
density increased in detergent resistant membrane fractions (DRM) in frontal and temporal cortices 
as a consequence of altered cholesterol metabolism (Molander-Melin et al., 2005). These findings 
all point to an association between GM2 upregulation and neurodegeneration. 
 
1.9 GM3 Ganglioside 
	
     GM3 is structurally the simplest ganglioside and is the precursor to all other ganglioside species 
(Yu et al., 2011). In early embryonic life, GM3 ganglioside is expressed abundantly within the 
brain (Ngamukote et al., 2007). However, GM3 is expressed only in very low levels in the adult 
brain of healthy rodents (Caughlin et al., 2015; Whitehead et al., 2011). GM3 is upregulated in 
response to neurodegeneration in several models of neuronal injury. GM3 has been shown to 
increase transiently around the infarcted region following middle cerebral artery occlusion 
(MCAO)-stroke injury in mouse brains (Whitehead et al., 2011). Furthermore, Caughlin et al. 
showed that the degree of accumulation of GM3 corresponded to the severity of the 
neurodegenerative insult, with a greater accumulation observed in the most severe injury models 
(Caughlin et al., 2015). Oikawa et al. reported that GM3 accumulation was associated with 
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increase deposition of amyloid beta (Aß), and this led to amyloid angiopathy in transgenic mice 
expressing a mutant amyloid precursor protein with defected GalNAcT gene, suggesting that GM3 
accumulation may play a role in AD pathology (Oikawa et al., 2009). These preclinical studies 
suggest a direct link between GM3 and the development of brain pathology. 
     There is a body of evidence which shows the inhibitory effect of GM3 on angiogenesis and 
tumor growth (Abate, Mukherjee, & Seyfried, 2006; H & L, 2009; Toledo, Suzuki, Handa, & 
Hakomori, 2005). A study in malignant mouse astrocytoma cells (CT-2A) transfected with the 
antisense (GalNAc-T) plasmid, the enzyme that converts GM3 to GM2, showed an elevation of 
GM3 ganglioside. This increase in GM3 was associated with a reduction in tumor vascularity, as 
measured through vascular density and vascular endothelial growth factor (VEGF) (Abate et al., 
2006; Seyfried & Mukherjee, 2010). Another study showed that GM3 inhibited endothelial 
proliferation that was induced by malignant cells in a neuroblastoma cell line (Alessandri, 
Cornaglia-Ferraris, & Gullino, 1997).  
     GM3 accumulation is also associated with cell death and apoptosis. A study in a Chinese 
hamster ovary mutant cell line expressing metastasis-suppressing gene product CD82 or CD9, 
showed that increased GM3 was associated with an increase in cell death and an inhibition in cell 
motility (Ono, Handa, Withers, & Hakomori, 1999). Additionally, Toledo et al. found that GM3 
affected the interaction between integrin proteins and fibroblast growth factor receptors in human 
embryonal WI38 fibroblasts, and eventually inhibited cell growth, motility, and adhesion (Toledo 
et al., 2005).  
     It has been observed that there is a potential influence of GM3 on the development and 
pathogenesis of diabetic nephropathy. GM3 levels increased following hyperglycemia, which led 
to compromised renal endothelial regeneration and disrupted renal function via modulating VEGF 
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and Akt signaling pathways that subsequently induced apoptosis (Vukovic, Bozic, Markotic, 
Ljubicic, & Kurir, 2015). Moreover, abundant GM3 was found to associate laterally with insulin 
receptor (IR), which inhibited insulin-induced autophosphorylation needed for insulin-mediated 
metabolic signaling (Lipina & Hundal, 2015; Tagami et al., 2002). This evidence supports the 
correlation of GM3 accumulation with apoptosis, renal damage, insulin resistance and vascular 
inhibition. 
     All of the above-mentioned studies indicate that GM1 is associated with neuroprotective 
signaling while GM2 and GM3 are upregulated in response to neurodegenerative injury. Thus, if 
we were to increase GM1 levels and / or prevent the accumulation of GM2 and GM3, we may 
uncover a new lipid therapeutic approach to reduce neuronal damage. One avenue to accomplish 
this is to perturb the ganglioside metabolic pathway using ganglioside enzyme modifiers such as 
Ambroxol. 
 
1.10 Ambroxol 
	
     Previous studies have identified several agents that can perturb ganglioside homeostasis. One 
such candidate is Ambroxol, an expectorant antitussive mucolytic drug which is clinically used in 
the treatment of obstructive lung diseases, and has anti- inflammatory and antioxidant effects 
(Štětinová, Herout, & Květina, 2004). The chemical formula of Ambroxol is C13H18Br2N2O 
(Figure 4). Ambroxol has been shown to modulate glucocerebrosidase (GCase), the enzyme 
catalyzes the cleavage from glucosylceramide to the ceramide, in Gaucher’s disease (GD) 
fibroblast (Maegawa et al., 2009). Furthermore, Ambroxol upregulated transcription of GCase and 
a host of other lysosomal markers including lysosomal integral membrane protein-2 (LIMP-2), 
involved in GCase trafficking to lysosomes and the enzyme activator saposin (Sap) C in a 
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fibroblast of PD with defective GCase (Ambrosi et al., 2015; McNeill et al., 2014).  
     Moreover, Ambroxol minimized oxidative stress markers and improved lysosomal enzymes in 
fibroblasts with GCase mutations (McNeill et al., 2014). In clinical trials, Narita et al. reported that 
Ambroxol modulated GCase in lymphocytes of neuronopathic GD patients. They also observed 
motor dysfunction improvement including gait and myoclonus, a reduction in seizure frequency, 
and an improvement in eye movements  (Narita et al., 2016). Indicating that Ambroxol plays 
potential role on perturbing lysosomal biochemistry, and demonstrates  promising results in 
improving neurological disorders. 
     Ambroxol has also demonstrated protective effects  on ischemic damage (Jiang et al., 2013; 
Röhnert et al., 2012). Intravenous administration of Ambroxol in Wistar rats exposed to hepatic 
ischemia reperfusion injury showed a reduction in the hepatocyte histological damage and a 
decrease in liver enzymes level. This occurred via activation of antioxidant enzymes such as 
superoxidedismutase (SOD), catalase (CAT), and glutathione (GSH) reductase, and an 
enhancement of anti-apoptotic signaling pathways (Jiang et al., 2013). Rohnert et al. found that 
Ambroxol improved neuronal ischemia reperfusion in in vitro and in vivo models. Co-
administration of Ambroxol with a reducing agent such as lipoic acid alleviated ischemia induced 
neuronal damage in organotypic hippocampal slice cultures exposed to oxygen glucose deprivation 
(OGD) and in gerbils exposed to two vessel occlusion (Röhnert et al., 2012). Ambroxol has also 
demonstrated a protective effect in liver transplant preservation. Drews et al. demonstrated that 
Ambroxol conferred protection in a rat liver transplantation model preserved in hypothermic 
conditions. Bile flow was increased, liver enzymes were in normal range, and histological damage 
in the transplanted livers was reduced (Drews et al., 2000).  
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Figure 4. Ambroxol Hydrochloride structure. 
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     Based on the above studies, Ambroxol has a perturbing influence on the lysosomal 
biochemistry, and shows a protective potential in alleviating ischemic damage. For these reasons, 
Ambroxol was used in this study in order to enhance neuronal survival and to protect neurons 
against injury. 
 
1.11 Cerebral Ischemia and Neuronal Damage 
	
     Cerebral ischemia is a very severe metabolic disorder that results from an interruption in the 
blood supply to the brain (Lai, Shyu, & Wang, 2011). Cerebral ischemia is considered the third 
leading cause of death and a major cause of disability in industrialized countries (Dirnagl, Iadecola, 
& Moskowitz, 1999).  
     Neuronal death following hypoxic damage can occur in one of two ways including necrosis or 
apoptosis (Xu & Zhang, 2011). Necrosis is a form of cell death which is triggered by energy 
depletion, and resulted from either physical or chemical insult on the cell (Rami, Bechmann, & 
Stehle, 2008; Yamashima & Oikawa, 2009). Cell death in the infarct core occurs by necrosis since 
the core is the area which suffers most from nutrient deprivation. Cells swell which leads to 
damage in the surrounding tissue, eliciting an inflammatory response which is aggravated by 
leukocyte extravasation and recruitment of resident microglia (Bruce-keller, 1999; Stoll, Jander, 
& Schroeter, 1998). Apoptosis is a delayed form of cell death following cerebral ischemia. It 
includes shrinking in the cell, DNA condensation and fragmentation, and formation of apoptotic 
bodies (Xu & Zhang, 2011). Apoptotic cell death occurs in the area around the infarct core, termed 
the penumbra, which is less affected by blood supply restrictions (Broughton, Reutens, & Sobey, 
2009; Mattson, Culmsee, & Zai, 2000) 
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1.12 The Ischemic Cascade 
	
     It is well established that neuronal death occurs via different pathways as a consequence of 
energy depletion following nutrient and oxygen restriction. Energy failure activates glutamate 
receptors which leads to the release of the excitatory neurotransmitter, glutamate. An accumulation 
of the excitatory glutamate triggers the opening of Ca2+ channels which leads to intracellular Ca2+ 
overload and extracellular release of Na+ and K+. This process subsequently diffuses fluids inside 
the cell, and results in cellular swelling (Lipton, 1999; Mehta, Manhas, & Raghubir, 2007). 
Proteases, lipases, and endonucleases are activated as a result of the increase in the intracellular 
Ca2+. Free radicals are produced from injured mitochondria or arachidonic acid metabolism and 
nitic oxide (NO) is generated from L-arginine through nitrous oxide synthase (NOS). Increase in 
free radicals causes cell membrane disintegration, mitochondria and DNA damage, and ultimately 
cell death  (Hall, 1995; Mattson et al., 2000; Suh et al., 2008; Zhao, Li, & Maiese, 2005). 
 
1.13 Ischemic Damage in Oxygen Glucose Deprivation  
	
     In vitro models of ischemia have long been considered as a useful model for studying the 
underlying mechanisms and pathways of neuronal injury (Choi, 1993; Cimarosti & Henley, 2008; 
Tasca, Dal-cim, & Cimarosti, 2015; Velly et al., 2003). Cerebral ischemia can be induced in vitro 
by anoxia only, in which neurons or  brain slices are incubated in glucose contained media in 
deoxygenated chamber, resulting in cell death similar to that observed  in vivo (Acker, 2004). Cell 
damage can also be produced by omitting both oxygen and glucose to create the in vitro ischemia 
or OGD model (Martin, Lloyd, & Cowan, 1994). 
     Experimental studies suggest that there are some differences between in vitro ischemia and 
ischemia induced in vivo. Energy depletion is less severe in in vitro ischemia which results in a 
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delay in glutamate release and prolonged cell death induction time. In addition, the absence of 
resident inflammatory cells such as microglia and astrocytes, eliminates the structural interactions 
that contribute to neuronal damage (Del Zoppo et al., 2007) . Although, in vivo cerebral ischemia 
and in vitro OGD differ in certain aspects, experimental studies of the in vitro models showed 
similar positive results in the final outcome (Arumugam et al., 2007).  
 
1.14 Rationale 
	
     Gangliosides play a pivotal role in neuronal injury, survival, and repair. GM1 ganglioside has 
been found to be abundantly expressed in healthy rodent brains (Caughlin et al., 2015; Whitehead 
et al., 2011), and plays a role in cell repair after injury in animal and human models of cerebral 
ischemia and PD (Lazzaro et al., 1994; Schneider et al., 2012). Furthermore, GM1 ganglioside 
deficiency in nigral dopaminergic neurons is associated with PD symptoms (Wu, Lu, Kulkarni, & 
Ledeen, 2012). Previous studies have shown that Ambroxol modulates ganglioside degradative 
enzymes in Parkinson’s and Gauchers’s disease (Ambrosi et al., 2015; Maegawa et al., 2009; 
McNeill et al., 2014) and has shown a protective effect following ischemia reperfusion injury 
(Jiang et al., 2013). Based on these findings, we sought to determine if Ambroxol had any effects 
on neuronal ganglioside expression profiles and to compare the neuroprotective potential of 
Ambroxol to exogenous GM1 treatment in neurons undergoing oxygen glucose deprivation 
(OGD). 
 
1.15 Hypothesis 
	
Treatment with Ambroxol will increase GM1 levels in primary cortical embryonic rat neurons and 
will prevent neuronal death caused by oxygen glucose deprivation reperfusion injury (OGD/R). 
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Prediction 1: Ambroxol treatment will increase GM1 ganglioside levels; and will have no effect 
on GM2 and GM3 gangliosides in primary cortical embryonic rat neurons. 
Prediction 2: Ambroxol treatment will confer neuroprotection against OGD/R injury in primary 
neurons, and this neuroprotective effect will be similar to the neuroprotective potential of the 
exogenously administered GM1. 
 
1.16 Objectives 
	
Objective 1: Determine if Ambroxol can intrinsically increase GM1 in primary cortical embryonic 
rat neurons. 
 
Objective 2: Compare the neuroprotective potential of Ambroxol with direct exogenous GM1 
treatment in primary cortical embryonic rat neurons exposed to OGD. 
 
Objective 3: Investigate GM1, GM2 and GM3 ganglioside levels in primary cortical rat neurons 
following OGD exposure. 
 
 
 
 
 
 
 
 
 
	 24	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
	
Section 2: METHODS 
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2.1 Culturing Cortical Neurons from Rat Embryo  
 
2.1.1 Animals 
 
     All experimental procedures were carried out aligned with the standards of Canadian Council 
on Animal Care, and protocols were approved by Western University Animal Use Subcommittee 
(Protocol 2014-016).  
2.1.2 Plate Preparation 
 
     To coat the plates, 7 % poly-L-Ornithine (molecular weight 30,000-70,000 Sigma, St. Louis, 
MO, USA) solution was prepared with distilled water. Glass cover slips were placed in each of the 
24-well plates and these were coated with 500 µL of the 7 % poly- L-Ornithine solution. Ten cm 
plates were coated with 10 mL of 7 % poly-L-Ornithine solution. All of the plates were incubated 
with the solution for 1 h at room temperature. The solution was then aspirated and washed three 
times with ddH2O. They were left to dry overnight at room temperature. 
2.1.3 Cortical Neuron Culture 
	
     Pregnant female Wistar rat was sacrificed by cervical dislocation, and embryos were surgically 
removed on embryonic day 18 (E18). The dissected uterus was removed and placed in a petri dish 
containing Hank’s balanced salt solution (HBSS, Wisent Bioproducts, St.Bruno, Quebec). Brain 
cerebral cortices from embryos were extracted, meninges were removed, and cortices were placed 
in a conical tube containing HBSS. The tube was centrifuged at 4000 g for 1 min at room 
temperature. HBSS was aspirated, and solution A containing 71% HBSS, 0.09% MgSO4 (1 M), 
and 29% trypsin (Sigma, St.Louis, MO, U.S.A.) was added, and the mixture was rotated at 37 ° C 
for 25 min in a heated chamber. After rotation, solution B containing 96% HBSS, 0.11% MgSO4 
(1 M), 2.4% DNase1 (10 mg/mL) (Roche Life Sciences, Indianapolis, IN), and 1.5% trypsin 
inhibitor (100 µ g/mL) (Roche Life Sciences, Indianapolis, IN) were added to the conical tube and 
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mixed. The tube was then centrifuged at 4000 g for 5 min at room temperature and HBSS was 
aspirated. Finally, solution C containing 89% HBSS, 0.21% MgSO4 (1 M), 5.8% DNase1 (10 
mg/mL), and 4.5% trypsin inhibitor (100 µ g/mL) was added to the resulting cell pellet. The cells 
were triturated 10− 15 X until the solution appeared homogeneous. Cells were then centrifuged at 
4000 g for 5 min and the supernatant was aspirated. The cell pellet was resuspended in neural basal 
plating media containing 96% neural basal media (NBM, Wisent Bioproducts, St. Bruno, Quebec), 
2% B27 supplement (Invitrogen, Carlsbad, CA), 0.8% N2 supplement (Invitrogen, Carlsbad, CA), 
0.5% penicillin/streptomycin (Invitrogen, Carlsbad, CA), 0.25% Glutamax (Invitrogen, Carlsbad, 
CA), and 0.1% amphotericin B solution (Sigma, St. Louis, MO, U.S.A.). Cells were counted in 
two corner squares of the hemocytometer under the microscope by adding 20 µL of Trypan Blue 
to a 20 µL of cell suspension. The media was added to the cortical cell suspension to create a stock 
suspension at 1.0 x 10 6 cells/ml. The cells were plated at a density of 0.5 x 10 6 cells/well by adding 
500 µL of the 1.0 x 10 6 cells/mL solution to the 24-well plates and 1.0 x 10 7 cells/plate by adding 
10 mL of the 1.0 x 10 6 cells/mL solution to the 10 cm plates. Cells were kept in an incubator at 37 
°C and 5 % CO2. Half of the media was exchanged every 2 days until 10 days in vitro (DIV). Eight 
to ten biological replicates (n = 8-10) were produced per experimental group for the 24-well plates, 
and six biological replicates (n = 6) were produced per experimental group for the 10 cm plates. 
Three biological replicates were performed for each study. 
 
2.2 Ambroxol Treatment 
	
     A	1 mM stock solution of Ambroxol (Sigma Aldrich, Oakville, Canada) was prepared and 
diluted in dimethylsulfoxide (DMSO). Neurons at DIV 10 were treated with either 5, 10 or 20 µM 
of Ambroxol for 1 h, 6 h and 24 h. These doses were chosen based on previously published reports 
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(Jiang et al., 2013; Röhnert et al., 2012). 
 
2.3 Glutamate Exposure 
	
     A 10 mM stock solution of glutamate (L (+)-glutamic acid 99%, Acros Organics, Thermo Fisher 
Scientific, New Jersey, U.S.A.) was prepared and diluted in glutamate solution 10 mM phosphate-
buffered saline (PBS). On DIV 10, primary cortical neurons were exposed to 100 µM of glutamate, 
a concentration previously shown to be effective at killing neurons (Park et al., 2016). Neurons 
exposed to glutamate for 6 and 24 h. 
 
2.4 GM1 Treatment 
	
     GM1 stock solution was prepared by directly dissolving GM1 (Sigma, St. Louis, MO, U.S.A.) 
in neural basal media (NBM) to achieve a final concentration of 1 mM. Neurons in 24-well plates 
or 10 cm plates were pretreated with 25 µM of GM1 24 h prior to OGD exposure.  
 
2.5 OGD Exposure 
	
     Neurons were kept in 24-well plates containing 0.5 ml/well or 10 cm plates containing 10 ml 
glucose free Balanced Salt Solution (BSS) under 95% N2/5% CO2 at 37°C for 1 h in deoxygenated 
chamber. Oxygen was flushed out from the chamber using nitrogen. After 1 h incubation, the BSS 
buffer was replaced with the original old medium, and reperfusion was performed for 6 and 24 h. 
 
2.6 Cell Fixation and Immunofluorescence 
	
     Neurons on coverslips were treated with 1 mg/ml of propidium iodide (PI) 45 min before cell 
fixation to measure cell death. Neurons were fixed with 4% paraformaldehyde (PFA) for 20 min 
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and washed 3 X with 10 mΜ PBS. Neurons were incubated with primary antibodies rabbit anti-
GM1 (Abcam, Toronto, Canada), and mouse anti-GM3 (Amsbio, Cambridge, U.S.A) at a 
concentration of 1:100 diluted in 3% BSA (bovine Serum Albumin) for 24 h at 4 °C. Coverslips 
were then washed 3 X in 10 mM PBS and incubated with FITC-conjugated goat anti-rabbit or 
goat-anti-mouse secondary antibodies (1:200, Thermo Fisher Scientific, Waltham, MA, U.S.A.) 
for 2 h at room temperature. Coverslips were then washed 3 X with PBS and twice with ddH2O. 
 
2.7 Lipid Extraction 
	
     Lipids were extracted using a modified Folch method (Folch et al., 1957). Four 10 cm plates 
(in Ambroxol treatment study) or one 10 cm plates (in the OGD study) were used to create a single 
experimental replicate (n=1). Following PBS washing, cells were scraped using a cell scraper and 
collected into a glass tube. To the 0.8 volume parts of aqueous cell extract, 2 parts of methanol 
was added and homogenized using an automated homogenizer. Then, 1 part of chloroform was 
added to give one phase Chloroform:Methanol:H2O (C:M:W) = 1:2:0.8. This mixture was left at 
room temperature for 1 h with periodical vortexing. 1.2 parts of water was added to the sample for 
phase separation to achieve a final composition of C:M:W = 1:2:2. Sample was centrifuged at 2000 
rpm and the upper aqueous phase was collected. The lower phase in the glass tube was re-extracted 
with the theoretical upper phase of M:W = 2:2 and was centrifuged at 2000 rpm. The upper phase 
was added to the first extracted sample and 1 ml KCl was added. For ganglioside extraction, a 
solid phase extraction C18 column (Waters, Mississauga, Ontario) was used. The column was first 
washed with 10 mL of MeOH, 10 mL of CHCl3: MeOH (2:1), another 10 mL of MeOH, and 10 
mL of MeOH:0.1KCl (1:1). Then the upper phase cell extract was applied through the column 
twice. 20 mL of H2O was passed through the column. The sample was eluted with 2 mL of MeOH 
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and 10 mL of CHCl3: MeOH (1:1). Samples were dried under N2 gas and stored at -80 °C until 
analysis.  
2.8 Electrospray Ionization Mass Spectrometry Detection of Gangliosides 
	
2.8.1 Liquid Chromatography 
	
    Dried lipid extracts were diluted in 1 mL of CHCl3: MeOH (1:1) and were sonicated for 15 min 
prior to analysis. For liquid chromatography, a pump was used to pressurize the mobile phase 
mixed with the sample to be separated in a Luna 3 µm 100 Å NH2 LC column (150 x 1 mm; 
Phenomenex, Torrance, CA).  The mobile phase was composed from 2 solutions: A) 
acetonitrile/water (83:17) (1 mM ammonium formate); and B) acetonitrile/water (1:1) (50 mM 
ammonium formate). The initial gradient was held for 5 min for solution A:B = 100:0, converted 
linearly to A:B=25:75 for 5 min, then converted linearly to A:B=10:90 for 5 min and held there 
for 10 min. The flow rate was set to 0.15 mL/min and the temperature of the column was set to 40 
°C.  
2.8.2 Electrospray Ionization Mass spectrometry 
	
     Mass spectrometry was performed with a Waters QToF Micro (Waters, Mississauga, Ontario) 
instrument and the spectra were analyzed using Mass Lynx v4.1 software (Waters).  Flight tube 
voltage was set to 5630 V, microchannel plate detector voltage was set to 2700 V, source tube 
voltage was set to 3500 V and the sample cone was set to 40 V.  The source temperature was set 
to 100 °C and desolvation temperature was set to 300 °C. NaCsI was used to calibrate the 
instrument and GM1 standards from bovine brain were purchased from Avanti Polar Lipids 
(Alabaster, Alabama). Samples were run in negative ion mode. Each experimental replicate was 
analyzed three times to produce three technical replicates.  
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2.8.3 Quantification of Gangliosides 
	
     GM1, GM2 and GM3 gangliosides were identified in the chromatogram according to their mass 
to detect their elution time. The chromatogram was extracted to analyze the mass spectrum of the 
eluates, and the peak intensities of these gangliosides were recorded. To quantify these ganglioside 
species, the peaks were normalized in the following way, based on (Park, 2016). First, the peak 
intensities of GM1d16:1, GM1 d18:1, GM1 d20:1, GM2 d16:1, GM2 d18:1, GM2 d20:1, GM3 
d16:1, GM3 d18:1 and GM3 d20:1 ganglioside were summed for each technical replicate. Then 
the average of total lipid peak intensities from all of the runs was calculated. Considering the 
difference in the amount of lipids that were ran per sample, we calculated the quotient between the 
total lipid peaks relative to the average peak intensity of all runs. This number was divided by the 
peak intensities of each ganglioside peak. Moreover, it is known that when cells die, they detach 
from the plates resulting in a variation in the total amount of the starting lipids in each plate. In 
order to compensate for the differences in lipid extraction efficiency, DAPI cell counts was done 
to quantify the average number of cells present in each experimental settings. A factor was 
calculated relative to the control, and multiplied to the peaks of each ganglioside.  
 
2.9 Imaging 
	
     Images were taken using a Nikon Eclipse Ni (Nikon Instruments Inc, Melville, NY, USA) 
microscope. Analysis and quantification was done using ImageJ (Wayne Rasband, National 
Institute of Health, Bethesda, USA). 
     In order to calculate GM1 and GM3 pixel intensity per total and viable cell following Ambroxol 
treatment, a single cover slip was used to create a single experimental replicate (n=1) and three 
pictures from different regions of the cover slip were taken for triple technical replicates. GM1 
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and GM3 optical densitometry on control and Ambroxol treated cortical neurons was performed 
using ImageJ (Wayne Rasband, National Institute of Health, Bethesda, USA). DAPI images at 40 
x were taken using the Nikon Imaging Software Elements (Nikon, Melville, NY, USA). Total pixel 
intensity was calculated by dividing the mean grey value by the total cell count in the same image. 
Pixel intensity per viable cell was counted by dividing the mean grey value by the total number of 
the viable cells which was calculated by subtracting the PI positive cells from the total DAPI 
positive cells. 
     In order to assess cell death following Ambroxol (described in figure 9), the total number of PI 
positive neurons within each image was expressed as a percentage of PI positive neurons to total 
neurons present within the picture. The percentage of PI positive cells from three replicates gave 
an average of PI positive cells per experimental n. 
     To account for the number of cells present for each Ambroxol treatment time point, and to 
account for the total number of cells when assessing cell death following OGD exposure (described 
in figures 14&15), DAPI images at 20 x were taken using the Nikon Imaging Software Elements 
(Nikon). Five random squares were chosen. Within each of these squares, the total number of 
DAPI positive cells were counted and averaged to represent the total number of cells within the 
frame. 
      To assess the cell death following OGD exposure for each reperfusion time point, PI images 
at 20 x were taken using the Nikon Imaging Software Elements (Nikon). Five random squares 
were chosen. Within each of these squares, the total number of DAPI positive cells and PI positive 
cells were counted and averaged to represent the total number of cells and PI positive cells present 
within the same frame. The percentage of PI positive cells was calculated. 
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2.10 Data and Statistical Analysis 
	
     Experimental group means were calculated using Microsoft Excel. Statistical analysis was 
performed using Graph Pad Prism (version 7). Multiple group comparisons were done by one-way 
ANOVA followed by Tukey’s multiple comparison post-hoc tests. Data presented as mean ± SEM. 
Significance level was set to p ≤ 0.05. 
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3.1 Ambroxol Increases GM1 and Not GM3 Levels in Primary Cortical Neurons 
 
     Several in vitro and in vivo studies have used Ambroxol to test its anti-inflammatory and 
antioxidant activities (McNeill et al., 2014; Štětinová et al., 2004); however, the effects of 
Ambroxol on ganglioside metabolism has not yet been reported. Primary cortical embryonic rat 
neurons were cultured, and treated at DIV 10 with either 5, 10 or 20 µM of Ambroxol for either 1, 
6 or 24 h. Neurons were then fixed and labelled with antibodies against GM1 and GM3. 
    In these experiments, neurons treated with Ambroxol for up to 24 h exhibited similar 
morphology to untreated control neurons (Figures 5A,6A,7A). GM1 levels remained unchanged 
following 1 h of Ambroxol treatment at any dose (Figure 5B,C). Following 6 h of Ambroxol 
exposure, neurons that were treated with 10 µM Ambroxol showed no significant change in total 
GM1 signal (Figure 6B), however, GM1 signal was higher when measured in viable neurons only 
(p < 0.05) (Figure 6C). This is in contrast to neurons treated with 5 and 20 µM of Ambroxol, which 
were not different from untreated cells. At 24 h, GM1 expression then showed no significant 
change between the treatment groups and the control neurons (Figure 7B,C).  
	 35	
 
 
 
 
 
 
 
 
 
 
	 36	
	
Figure 5. Photomicrographs and quantification of GM1 labelling following 1 h Ambroxol 
treatment. (A) Photomicrographs of DIV 10 rat cortical neurons following 1 h exposure of 5, 10 
or 20 µM Ambroxol. Neurons were fixed and labeled with DAPI (blue), GM1 (green) and PI (red). 
Bars indicate 50 µm for each panel. (B &C) Quantification of GM1 pixel intensity per total and 
viable cell respectively, normalized to control neurons. Data is presented as mean ± SEM, and 
analyzed by one-way ANOVA followed by Tukey’s multiple comparisons test, n = 8 for each 
group. 
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Figure 6. Photomicrographs and quantification of GM1 labelling following 6 h Ambroxol 
treatment. (A) Photomicrographs of DIV 10 rat cortical neurons following 6 h exposure of 5, 10 
or 20 µM Ambroxol. Neurons were fixed and labeled with DAPI (blue), GM1 (green) and PI (red). 
Bars indicate 50 µm for each panel. (B &C) Quantification of GM1 pixel intensity per total and 
viable cell respectively, normalized to control neurons. Data is presented as mean ± SEM, and 
analyzed by one-way ANOVA followed by Tukey’s multiple comparisons test, * indicates 
statistical significance, p < 0.05, n = 7,8 for each group. 
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Figure 7. Photomicrographs and quantification of GM1 labelling following 24 h Ambroxol 
treatment. (A) Photomicrographs of DIV 10 rat cortical neurons following 24 h exposure of 5, 10 
or 20 µM Ambroxol. Neurons were fixed and labeled with DAPI (blue), GM1 (green) and PI (red). 
Bars indicate 50 µm for each panel. (B &C) Quantification of GM1 pixel intensity per total and 
viable cell respectively, normalized to control neurons. Data is presented as mean ± SEM, and 
analyzed by one-way ANOVA followed by Tukey’s multiple comparisons test, n = 8 for each 
group. 
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     GM3 levels were examined after 6 and 24 h of Ambroxol treatment at 10 µM of Ambroxol, the 
concentration that significantly changed GM1 expression. GM3 expression was compared to the 
expression in untreated neurons and 100 µM glutamate exposed neurons. Glutamate is known to 
induce cell death (Park et al., 2016), so it was used as a positive control. Loss of membrane 
integrity/cell death was examined using Propidium Iodine staining.  These experiments showed 
that Ambroxol did not significantly change GM3 expression at 6 h (Figure 8). At 24 h, there was 
a remarkable increase in cell death and GM3 expression in glutamate treated cells compared to 
untreated neurons (Figure 9A). Measuring GM3 pixel intensity, GM3 was significantly increased 
in glutamate treated cells compared to the control (p < 0.0001) (Figure 9B). Ambroxol did not 
result in a significant change in GM3 expression at 24 h (Figure 9).  
 
3.2 Ambroxol Does Not Cause Cell Death in Primary Cortical Neurons 
 
     Based on this study, Ambroxol changed GM1 expression in primary cortical neurons. However, 
cell viability following Ambroxol treatment has not been reported. PI positive cells were quantified 
following Ambroxol treatment in the experiments in Figures 4-8.  In each experiment, the number 
of PI-labeled cells did not increase at any Ambroxol concentration, for up to 24 h compared to 
control cells (Figure 10). 
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Figure 8. Photomicrographs and quantification of GM3 labelling following 6 h Ambroxol 
treatment. (A) Photomicrographs of DIV 10 rat cortical neurons following 6 h exposure of 10 µM 
Ambroxol. 100 µM glutamate treated neurons were used as a positive control. Neurons were fixed 
and labeled with DAPI (blue), GM3 (green), and PI (red). Bars indicate 50 µm for each panel. (B) 
Quantification of GM3 pixel intensity per total cell, normalized to control uninjured neurons. Data 
is presented as mean ± SEM, and analyzed by one-way ANOVA followed by Tukey’s multiple 
comparisons test, n = 7&8 for each group. 
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Figure 9. Photomicrographs and quantification of GM3 labelling following 24 h Ambroxol 
treatment. (A) Photomicrographs of DIV 10 rat cortical neurons following 24 h exposure of 10 
µM Ambroxol. 100 µM glutamate treated neurons were used as a positive control. Neurons were 
fixed and labeled with DAPI (blue), GM3 (green), and PI (red). Bars indicate 50 µm for each panel. 
(B) Quantification of GM3 pixel intensity per total cell, normalized to control uninjured neurons. 
Data is presented as mean ± SEM, and analyzed by one-way ANOVA followed by Tukey’s 
multiple comparisons test, **** indicates significance, p < 0.0001, n = 8 for each group. 
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Figure 10. Cell viability assay of primary rat neurons treated with Ambroxol. Neurons were 
treated with 5, 10 or 20 µM Ambroxol for 1 h, 6 h and 24 h (A, B and C respectively). At DIV 10, 
neurons were stained with 1 mg/ml (Propidium Iodide) PI 45 min before cell fixation. Data was 
normalized to control neurons, and analyzed by one-way ANOVA followed by Tukey’s multiple 
comparisons test. Data is presented as mean ± SEM, n = 7,8 for each experimental group. 
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3.3 LC-ESI-MS of Gangliosides in Primary Cortical Rat Neurons 
 
     To identify A-series gangliosides, using Waters QTOF ESI-MS instrument, chromatograms 
were generated from control uninjured neurons. Spectra were combined to visualize GM1, GM2, 
and GM3 and its d16:1, d18:1 and d20:1 sphingosine moieties. Peaks were identified in the spectra 
based on their mass to charge ratio (Figure 11A,B,C&D).  
 
3.4 LC-ESI-MS Analysis of Gangliosides in Neurons Following Ambroxol Treatment 
 
     Previous data in this study using immunofluorescence demonstrated that GM1 ganglioside was 
transiently increased following Ambroxol treatment in primary cortical neurons. For further 
validation, a time course of Ambroxol mediated changes in gangliosides GM1, GM2 and GM3 
was established using LC-ESI-MS. 
     Ambroxol showed no effect on GM1 d16:1 (Figure 12A). When assessing GM1 d18:1 levels, 
Ambroxol treatment resulted in a significant increase at 6 h and 24 h post-treatment (p < 0.0001) 
(Figure 12B). Similarly, when measuring GM1 d20:1, Ambroxol treatment resulted in a significant 
increase at 6 h which remained elevated at 24 h (p < 0.0001) (Figure 12C).  
     GM2 d16:1 and d20:1 levels did not change following Ambroxol treatment (Figure 13A,C), 
however, GM2 d18:1 increased significantly at both 6 h (p < 0.0001), and 24 h following 
Ambroxol treatment (p < 0.0001) (Figure 13B). 
     GM3 d16 and d20:1 levels did not change throughout the course of Ambroxol treatment 
compared to control neurons (Figure 14A,C). GM3 d18:1 increased 6 h following Ambroxol 
treatment (p < 0.05), and returned to control levels at 24 h (Figure 14B). 
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Figure 11. Mass spectrum (ESI-MS-) of control neurons. Displaying (A) a-series gangliosides: 
GM1, GM2, GM3. (B) Spectrum of GM3 displaying the d16:1, d18:1, and d20:1 sphingosine 
moieties. (C) Spectrum of GM2 displaying the d16:1, d18:1, and d20:1 sphingosine moieties. (D) 
Spectrum of GM1 displaying the d16:1, d18:1, and d20:1 sphingosine moieties. 
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Figure 12. Quantification of GM1 levels in cortical neurons treated with Ambroxol. 
Normalized peak intensity from Waters QTOF ESI-MS instrument of (A) GM1 d16:1, (B) GM1 
d18:1, (C) GM1 d20:1 from DIV 10 rat cortical neurons following treatment with 10 µM 
Ambroxol for either 6 h or 24 h. Peak intensities were individually normalized to account for 
differences in lipid extraction efficiency and cell number. Each experimental Ambroxol time point 
value was obtained from calculating the average of three technical replicates. Experimental group 
data represented as % mean change from controls ± SEM, * indicates statistical significance from 
control untreated neurons, ** p < 0.05, *** p = 0.0003, **** p < 0.0001, one-way ANOVA, 
Tukey’s multiple comparisons test, n = 6 per experimental time point.  
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Figure 13. Quantification of GM2 levels in cortical neurons treated with Ambroxol. 
Normalized peak intensity from Waters QTOF ESI-MS instrument of (A) GM2 d16:1, (B) GM2 
d18:1, (C) GM2 d20:1 from DIV 10 rat cortical neurons following treatment with 10 µM 
Ambroxol for either 6 h or 24 h. Peak intensities were individually normalized to account for 
differences in lipid extraction efficiency and cell number. Each experimental Ambroxol time point 
value was obtained from calculating the average of three technical replicates. Experimental group 
data represented as mean % change from controls ± SEM, * indicates statistical significance from 
control untreated neurons, *** p = 0.0003, **** p < 0.0001, one-way ANOVA, Tukey’s multiple 
comparisons test, n = 6 per experimental time point.  
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Figure 14. Quantification of GM3 levels in cortical neurons treated with Ambroxol. 
Normalized peak intensity from Waters QTOF ESI-MS instrument of (A) GM3 d16:1, (B) GM3 
d18:1, (C) GM3 d20:1 from DIV 10 rat cortical neurons following treatment with 10 µM 
Ambroxol for either 6 h or 24 h. Peaks intensities were individually normalized to account for 
differences in lipid extraction efficiency and cell number. Each experimental Ambroxol time point 
value was obtained from calculating the average of three technical replicates. Experimental group 
data represented as mean % change from controls ± SEM, * indicates statistical significance from 
control un treated neurons, p < 0.05, one-way ANOVA, Tukey’s multiple comparisons test, n = 6 
per experimental time point.  
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3.5 Assessing Neuroprotective Potential of Ambroxol in Neurons Exposed to Oxygen 
Glucose Deprivation  
     Ambroxol has been previously shown to protect against cell death following hepatic ischemia-
reperfusion injury (Jiang et al., 2013). We therefore assessed the neuroprotective potential of 
Ambroxol to prevent neuronal cell death following OGD/R injury. DIV 10 primary neurons were 
pre-treated with 10 µM Ambroxol for 6 h prior to OGD exposure, a concentration work in this 
thesis results in increased GM1 expression (Figure 5). Direct pre-treatment with GM1 was also 
performed to evaluate the neuroprotective potential of Amboxol compared to exogenous GM1 
administration. PI was used to assess cell death (Figures 15A,16A). 
     Following OGD and 6 h reperfusion, there was no significant increase in cell death in neurons 
that were exposed to OGD/R injury compared to uninjured neurons (Figure 15B).  Ambroxol or 
GM1 pretreatment did not protect against neuronal cell death at 6 h following OGD/R exposure 
(Figure 15A,B). 
      By 24 h of reperfusion, neurons that were exposed to OGD showed 50% increase in cell death 
compared to control neurons; however, this increase was not statistically significant. Ambroxol 
pretreatment showed no significant change in cell death compared to the control. However, GM1 
pre-treatment showed an increase in cell viability compared to the OGD injured cells (p < 0.05) 
(Figure 16A,B).  
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Figure 15. Assessing cell viability in neurons exposed to 1 h OGD, followed by 6 h 
reperfusion. (A) Photomicrographs of DIV 10 rat cortical neurons that were treated with 10 µM 
Ambroxol 6 h prior to OGD or treated with 25 µM GM1 24 h prior to OGD, followed by 6 h 
reperfusion. Neurons were fixed and labeled with DAPI (blue), and PI (red). Bars indicate 50 µm 
for each panel. (B) Quantification of PI positive cells normalized to control uninjured neurons. 
Data presented as mean ± SEM, analyzed by one-way ANOVA, Tukey’s multiple comparisons 
test, P > 0.05, n = 10 per experimental group. 
 
      
     
 
 
 
 
&RQWURO 2*'$[
$
%
&WU
2*
'5
2*
'
$[
2*
'
*0






3,
SR
VL
WLY
H
FH
OOV
UH
OD
WLY
H
WR
FR
QW
UR
O
2*'5 2*'*0
'$3,3,
	 54	
	
Figure 16. Pretreatment with GM1 for 24 h protects neurons following 1 h OGD and 24 h 
reperfusion. (A) Photomicrographs of DIV 10 rat cortical neurons that were treated with 10 µM 
Ambroxol 6 h prior to OGD exposure or treated with 25 µM GM1 24 h prior to OGD exposure, 
followed by 24 h reperfusion. Neurons were fixed and labeled with DAPI (blue), and PI (red). Bars 
indicate 50 µm for each panel. (B) Quantification of PI positive cells normalized to control 
neurons. Data presented as mean ± SEM, and analyzed by one-way ANOVA followed by Tukey’s 
posthoc tests, * indicates statistical significance from control neurons GM1 treated group. P < 0.05, 
n = 10 per experimental group. 
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3.6 LC-ESI-MS Analysis of Gangliosides in Neurons Exposed to Oxygen Glucose 
Deprivation and Pretreated with Ambroxol or GM1  
     Our previous ESI-MS and immunocytochemistry results showed that Ambroxol caused a shift 
in ganglioside levels in primary neurons. This led us to investigate the effect of OGD reperfusion 
injury on the different species of GM1, GM2 and GM3 (d16:1, d18:1, and d20:1) levels in primary 
neurons pretreated with Ambroxol or pretreated with exogenous GM1. Lipids were extracted at 6 
h and 24 h reperfusion time points following OGD.  
     At 6 h reperfusion, GM1 d16:1, GM1 d18:1 and GM1 d20:1 were significantly increased in 
neurons pretreated with GM1 (p < 0.05) (Figure 17A,B,C). GM1 d16:1 and GM1 d20:1 showed 
no significant change in OGD exposed cells and in cells that were pretreated with Ambroxol 
(Figure 17A,C). GM1 d18:1 reduced significantly in OGD exposed cells and in cells pretreated 
with Ambroxol (p < 0.05) (Figure 17B). GM2 d16:1, GM2 d18:1 and GM2 d20:1 decreased 
significantly in cells that were exposed to OGD injury (p < 0.05) (Figure 18A,B,C). GM2 d18:1 
showed significant decrease in cells pretreated with Ambroxol (p < 0.05) (Figure 18B). GM2 d16:1 
and GM2 d20:1 showed no significant change in cells pretreated with Ambroxol. GM1 
pretreatment did not result in a significant change in GM2 d16:1and GM2 d20:1 levels (Figure 
18A,C). GM2 d18:1 levels were significantly decreased in neurons pretreated with GM1 (Figure 
18B). GM3 d16:1, GM3 d18:1 and GM3 d20:1 were significantly reduced in OGD exposed cells 
and in cells that were pretreated with Ambroxol (p < 0.05) (Figure 19A,B,C). GM3 d20:1 did not 
show significant change in cells that were pretreated with GM1 (Figure 19C). GM3 d16:1 and 
GM3 d18:1 showed significant decrease in GM1 pretreated neurons (Figure 19A,B).  
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Figure 17. Quantification of GM1 levels in cortical neurons exposed to OGD, pretreated with 
Ambroxol or GM1, and reperfused for 6 h. Normalized peak intensity from Waters QTOF ESI-
MS instrument of (A) GM1 d16:1, (B) GM1 d18:1 and (C) GM1 d20:1 from DIV 10 rat cortical 
neurons following treatment with 10 µM Ambroxol for 6 h prior to OGD or with 25 µM GM1 24 
h before OGD exposure. Peak intensities were individually normalized to account for differences 
in lipid extraction efficiency and cell number. Each experimental group value was obtained from 
calculating the average of three technical replicates. Experimental group data represented as mean 
% change from controls ± SEM, * indicates statistical significance from control uninjured neurons, 
p < 0.0001, one-way ANOVA, Tukey’s multiple comparisons test, n = 6 per experimental group.  
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Figure 18. Quantification of GM2 levels in cortical neurons exposed to OGD, pretreated with 
Ambroxol or GM1, and reperfused for 6 h. Normalized peak intensity from Waters QTOF ESI-
MS instrument of (A) GM2 d16:1, (B) GM2 d18:1 and (C) GM2 d20:1 from DIV 10 rat cortical 
neurons following treatment with 10 µM Ambroxol for 6 h prior to OGD or with 25 µM GM1 24 
h before OGD. Peak intensities were individually normalized to account for differences in lipid 
extraction efficiency and cell number. Each experimental group value was obtained from 
calculating the average of three technical replicates. Experimental group data represented as mean 
% change from controls ± SEM, * indicates statistical significance from control uninjured neurons, 
* p < 0.05, **** p < 0.0001, one-way ANOVA, Tukey’s multiple comparisons test, n = 6 per 
experimental group.  
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Figure 19. Quantification of GM3 levels in cortical neurons exposed to OGD, pretreated with 
Ambroxol or GM1, and reperfused for 6 h. Normalized peak intensity from Waters QTOF ESI-
MS instrument of (A) GM3 d16:1, (B) GM3 d18:1 and (C) GM3 d20:1 from DIV 10 rat cortical 
neurons following treatment with 10 µM Ambroxol for 6 h prior to OGD or with 25 µM GM1 24 
h before OGD. Peak intensities were individually normalized to account for differences in lipid 
extraction efficiency and cell number. Each experimental group value was obtained from 
calculating the average of three technical replicates. Experimental group data represented as mean 
% change from controls ± SEM, * indicates statistical significance from control uninjured neurons, 
* p < 0.05, *** p = 0.0001, **** p < 0.0001, one-way ANOVA, Tukey’s multiple comparisons 
test, n = 6 per experimental group.  
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     At 24 h reperfusion, GM1 d18:1 significantly reduced following OGD injury (p < 0.05) while 
GM1 d16:1 and GM1d20:1 showed no significant change compared to the control (Figure 
20A,B,C). Ambroxol pretreatment recovered GM1 d18:1 in OGD exposed cells, and had no 
significant change on GM1 d16:1 and GM1 d20:1 compared to the control (Figure 20A,B,C). GM1 
pretreatment significantly enhanced GM1 d16:1, GM1 d18:1 and GM1 d20:1 levels compared to 
the control (p < 0.05) (Figure 20A,B,C). GM2 d16:1 and GM2 d20:1 did not display a significant 
change in OGD stressed cells or in cells pretreated with Ambroxol (Figure 21A,C). GM2 d18:1 
showed a significant decrease in cells exposed to OGD (p < 0.05) while did not exhibit a significant 
change in cells pretreated with Ambroxol (Figure 21B). GM1 pretreatment exhibited a significant 
increase in GM2 d18:1 and GM2 d20:1 (p < 0.05) while had no significant change on GM2 d16:1 
compared to the control (Figure 21A,B,C). GM3 d16:1, GM3 d18:1 and GM3 d20:1 showed no 
significant change in cells that were pretreated with Ambroxol or GM1 (Figure 22A,B,C). 
However, OGD stress exhibited a significant decrease in GM3 d18:1 (p < 0.05), and had no 
significant change on GM3 d16:1 and GM3 d20:1 compared to the control (Figure 22A,B,C). 
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Figure 20. Quantification of GM1 levels in cortical neurons exposed to OGD, pretreated with 
Ambroxol or GM1, and reperfused for 24 h. Normalized peak intensity from Waters QTOF 
ESI-MS instrument of (A) GM1 d16:1, (B) GM1 d18:1 and (C) GM1 d20:1 from DIV 10 rat 
cortical neurons following treatment with 10 µM Ambroxol for 6 h prior to OGD or with 25 µM 
GM1 24 h before OGD. Peak intensities were individually normalized to account for differences 
in lipid extraction efficiency and cell number. Each experimental group value was obtained from 
calculating the average of three technical replicates. Experimental group data represented as mean 
% change from controls ± SEM, * indicates statistical significance from control uninjured neurons, 
**** p < 0.0001, && indicates statistical significance from Ambroxol pretreated neurons, p = 
0.0021, one-way ANOVA, Tukey’s multiple comparisons test, n = 6 per experimental group.  
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Figure 21. Quantification of GM2 levels in cortical neurons exposed to OGD, pretreated with 
Ambroxol or GM1, and reperfused for 24 h. Normalized peak intensity from Waters QTOF 
ESI-MS instrument of (A) GM2 d16:1, (B) GM2 d18:1 and (C) GM2 d20:1from DIV 10 rat 
cortical neurons following treatment with 10 µM Ambroxol for 6 h prior to OGD or with 25 µM 
GM1 24 h before OGD. Peak intensities were individually normalized to account for differences 
in lipid extraction efficiency and cell number. Each experimental group value was obtained from 
calculating the average of three technical replicates. Experimental group data represented as mean 
% change from controls ± SEM, * indicates statistical significance from control uninjured neurons, 
* and ** p < 0.05, *** p = 0.0006, one-way ANOVA, Tukey’s multiple comparisons test, n = 6 
per experimental group.  
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Figure 22. Quantification of GM3 levels in cortical neurons exposed to OGD, pretreated with 
Ambroxol or GM1, and reperfused for 24 h. Normalized peak intensity from Waters QTOF 
ESI-MS instrument of (A) GM3 d16:1, (B) GM3 d18:1 and (C) GM3 d20:1 from DIV 10 rat 
cortical neurons following treatment with 10 µM Ambroxol for 6 h prior to OGD or with 25 µM 
GM1 24 h before OGD. Peak intensities were individually normalized to account for differences 
in lipid extraction efficiency and cell number. Each experimental group value was obtained from 
calculating the average of three technical replicates. Experimental group data represented as mean 
% change from controls ± SEM, * indicates statistical significance from control uninjured neurons, 
p = 0.0006, one-way ANOVA, Tukey’s multiple comparisons test, n = 6 per experimental group. 
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Section 4: DISCUSSION 
	 64	
     Gangliosides play an important role in cell signaling which regulates neural development, 
neuroregeneration and neurodegeneration (Stojiljković et al., 1996; Wang, Cheng, Wakade, & Yu, 
2014; Whitehead et al., 2011). Furthermore, gangliosides have been linked to the pathogenesis of 
certain diseases in the nervous system (Koga et al., 1990; Maglione et al., 2010; Schneider et al., 
2013). Gangliosides exist in a state of equilibrium within the healthy brain. A shift in this 
homeostasis from the neuroprotective complex species GM1 to simple species GM2 and GM3 has 
been linked to neurodegeneration (Caughlin et al., 2015; Schneider, 2018; Whitehead et al., 2011). 
GM1 ganglioside in particular exerts several neuroprotective effects and is expressed abundantly 
in healthy mammalian brains (Liu et al., 2005; Park et al., 2016; Whitehead et al., 2011). Previous 
studies have used Ambroxol in both in vitro and in vivo models of neurological disease whereby 
it was found to modulate lysosomal enzymes and lead to neurological improvements (Ambrosi et 
al., 2015; McNeill et al., 2014). However, the effect of Ambroxol on ganglioside expression 
profiles has not yet been reported. Thus, we hypothesized that treatment with Ambroxol would 
increase GM1 levels in primary cortical embryonic rat neurons and would prevent neuronal death 
caused by OGD/R injury.  
     In this study we demonstrated, for the first time, the temporal expression profile of A-series 
gangliosides GM1, GM2, and GM3 and their d16:1, d18:1 and d20:1 sphingosine moieties after 
Ambroxol treatment in primary embryonic cortical rat neurons. We predicted that Ambroxol 
treatment would increase GM1 levels but would have no effect on GM2 and GM3 gangliosides in 
primary neurons. Additionally, we compared the neuroprotective properties of both Ambroxol and 
exogenous administration of GM1 in neurons exposed to OGD/R injury. We predicted that 
Ambroxol treatment would confer neuroprotection against OGD/R injury in primary neurons, and 
this neuroprotective effect would be similar to the neuroprotective potential of the exogenously 
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administered GM1. We also demonstrated the expression profiles of GM1, GM2 and GM3 and 
their sphingosine moieties d16:1, d18:1 and d20:1 in primary neurons exposed to OGD/R injury. 
We predicted that GM2 and GM3 expression profiles would increase following OGD/R injury. 
 
4.1 Changes in Ganglioside Expression Profiles Following Ambroxol Treatment 
	
     By using ESI-MS and immunofluorescence, for the first time, we found that GM1 was 
enhanced significantly in primary cortical embryonic rat neurons following Ambroxol treatment. 
In particular, GM1 d18:1 and GM1 d20:1 increased significantly after 6 h and 24 h post Ambroxol 
treatment. Previous research has found that Ambroxol increases GCase in the ganglioside 
degradative pathway; however, the effect of Ambroxol on ganglioside levels had not yet been 
reported (Ambrosi et al., 2015; McNeill et al., 2014; Narita et al., 2016). Unexpectedly, this 
increase in GM1 was also associated with an increase in GM2 d18:1 after 6 h and 24 h of Ambroxol 
treatment, and with a transient increase in GM3 d18:1 after 6 h. This increase suggests that 
Ambroxol could modulate ganglioside expression profiles by inhibiting the lysosomal degradative 
enzymes that result in an increase in GM3 and the subsequent complex gangliosides. 
     Interestingly, the increase in GM2 and GM3 was not accompanied by an increase in cell death 
following Ambroxol treatment. However, this was not consistent with previous research, in which 
the accumulation of GM2 and GM3 was associated with cell death and neurodegeneration. 
Previous studies showed that GM2 accumulated in lysosomal storage diseases whereas GM3 
showed a stimulatory effect on apoptotic signaling (Kodama et al., 2011; Ono et al., 1999; Zervas 
et al., 2001). This inconsistent result could be explained by the remarkable increase in the 
neuroprotective GM1 in primary neurons following Ambroxol treatment, which may have masked 
the deleterious influence of GM2 and GM3 accumulation. 
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4.2 Ganglioside Expression Profiles Following OGD/R Injury in Primary Cortical Neurons 
	
     Work in this thesis demonstrated that GM1 d18:1 significantly decreased after 6 h and 24 h of 
reperfusion in OGD exposed neurons. d16:1, d18:1 and d20:1 of GM2 and GM3 were also 
significantly low following OGD/R injury. One possible reason for this robust decrease following 
OGD/R injury is the pH changes that occur following energy failure in the ischemic injury, which 
can cause adverse effects on biological processes. Nemoto and colleagues studied the cellular pH 
in rat brains following global brain ischemia and found that the pH changed from 7 to 6.2 within 
the first few minutes of ischemia which then continued to decrease as a result of lactic acidosis 
activation induced during reperfusion (Nemoto & Frinak, 1981). Indicating that the pH changes 
could activate lysosomal enzymes which resulted in a reduction in the gangliosides level. 
     This result did not match previous in vivo studies done in our lab which showed that GM1, 
GM2, and GM3 transiently increased following brain injury (Caughlin et al., 2015; Whitehead et 
al., 2011). Caughlin et al., found that GM1 d18:1 and GM3 increased significantly within 3 days 
in the infarct brain region of a combined model of Aβ toxicity and ET-1 injection. In the same 
study, Caughlin et al., demonstrated that GM2 increased at the lesion site 3 days following ET-1 
induced stroke (Caughlin et al., 2015). Another study conducted in our lab showed a significant 
increase in GM1 d18:1 at 24 h which peaked at day 7 following MCAO reperfusion injury in mice 
and also demonstrated upregulation of GM2 and GM3 around the infarct region (Whitehead et al., 
2011). Nevertheless, these studies were done in vivo in a complete biological system, while the 
current studies used an in vitro model of pure primary neuronal cultures which suggests that the 
increase that occurred in the in vivo models after brain injury could be a result of other brain cell 
activation including microglia due to an immunological response to the insult.  
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     We also found that GM1 d18:1 was significantly reduced 6 h after reperfusion and returned to 
control levels 24 h after reperfusion in OGD injured neurons pretreated with Ambroxol, and this 
level was significantly higher relative to the OGD injured neurons. This was associated with no 
increase in cell death in Ambroxol pretreated neurons after 24 h of reperfusion, indicating that 
Ambroxol could confer neuroprotective potential following OGD/R injury. This result matches 
with previous studies which showed the protective role of Ambroxol after ischemic damage. Jiang 
and group showed that Ambroxol attenuated ischemic damage in rat livers via activation of anti-
apoptotic signals and antioxidant enzymes (Jiang et al., 2013). Moreover, Rohnert et al., found that 
co-administering Ambroxol with a reducing agent improved ischemic damage induced by OGD 
in organotypic hippocampal slice cultures (Röhnert et al., 2012). Overall, it is possible that 
pretreating neurons with Ambroxol provided neuroprotection by recovering GM1 levels in neurons 
exposed to OGD, and this led to enhance lipid membrane integrity and reduce neuronal response 
to OGD injury. 
      As expected, we found that GM1 d16:1, d18:1, and d20:1 significantly elevated at 6 and 24 h 
after reperfusion in OGD injured neurons pretreated with exogenous GM1. This may indicate that 
the exogenous administration of GM1 could activate synthesis of endogenous GM1 in primary 
neurons as a neuroprotective mechanism following OGD/R injury. Unexpectedly, we found that 
GM2 d18:1 and GM2 d20:1 elevated 24 h after reperfusion in OGD injured neurons that were 
pretreated with exogenous GM1. One possible reason for this is that the remarkable increase in 
GM1 content in those neurons led to an activation of GM1 degradative enzymes which then 
resulted in an increase in GM2 levels. 
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4.3 The Neuroprotective Potential of the Exogenous GM1 Treatment 
	
     In this study, exogenous GM1 pretreatment showed an increase in cell viability in primary 
cortical embryonic rat neurons exposed to OGD and re-perfused for 24 h.  One possible mechanism 
of this neuroprotection is that the exogenously administered GM1 either compensated or enhanced 
the synthesis of the depleted endogenous GM1 after OGD/R injury, and this resulted in enhanced 
neuronal viability. This finding confirms previous in vitro and in vivo studies (Liu et al., 2005; 
Park et al., 2016; Schneider et al., 2013). Liu et al., found that GM1 conferred neuroprotection in 
rat hippocampal slices following OGD/R injury (Liu et al., 2005). Another study by Park et al., 
demonstrated that pretreating primary cortical rat neurons with 25 µM GM1 protected against 
glutamate induced cell death (Park et al., 2016). GM1’s neuroprotective potential has also been 
studied in clinical trials, in which Schneider and colleagues reported that GM1 treatment resulted 
in an improvement in motor function scores and a delay in overall disease progression in PD 
patients. Therefore, our data suggests that adding exogenous GM1 compensate the depleted 
endogenous GM1 in OGD injured neurons as a defense mechanism to enhance neuronal survival 
following OGD injury. 
 
4.4 Study Limitation 
	
     The first limitation to this study is that the antibodies used to detect gangliosides cannot 
distinguish between gangliosides based on their sphingosine moieties d16:1, d18:1 and d20:1. 
These antibodies can only recognize a specific glycan molecule at the cell surface, but cannot 
interact with the sphingosine backbone that is embedded within the lipid bilayer (Lopez, Lardone, 
Irazoqui, Maccioni, & Nores, 2002) . Thus, GM1 and GM3 antibody immunofluorescent images 
are not specific to a particular sphingosine moiety. 
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     Another limitation to the present study is the cross reactivity that could occur between the 
ganglioside antibodies and another species of ganglioside. For instance, anti-GM1 antibody 
obtained from Guillain-Barré syndrome patients’ sera was found to have a cross reactivity with 
GD1b ganglioside (Koga, Tatsumoto, Yuki, & Hirata, 2001). Thus, it is possible that the antibody 
used in this study bound nonspecifically to GD1b. However, this pitfall was addressed by using an 
ESI-MS technique which provides superior specificity to immunofluorescence by identifying 
gangliosides and their sphingosine moieties based on the mass to charge ratio (Ho et al., 2003; 
Merrill, Sullards, Allegood, Kelly, & Wang, 2005). 
     Another potential limitation to the current study is that LC-ESI-MS and immunofluorescence 
techniques vary in their sensitivity and detection methodology. In this study we found that the 
GM3 expression profile was not consistent between the two techniques. The immunofluorescence 
technique is mainly qualitative as gangliosides are only detected based on the binding of the 
antibody with a certain ganglioside epitope which resulted in low specificity. LC-ESI-MS, on the 
other hand, is a very specific and sensitive technique in analyzing molecules of interest based on 
their mass to charge ratio (Ho et al., 2003). Therefore, this inconsistency could be a result of the 
differences between the two techniques. 
 
4.5 Future Studies 
	
     This is the first study to analyze GM1, GM2 and GM3 gangliosides expression profiles in 
primary cortical embryonic rat neurons following Ambroxol treatment. Ambroxol was used in 
order to increase GM1 levels in primary neurons and to enhance neuronal survival following OGD. 
Currently, we know how A-series gangliosides are expressed in neurons treated with Ambroxol; 
however, an explanation of the mechanisms underlying this expression is fundamental. A previous 
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study showed that Ambroxol changed the pH in the lamellar bodies; lysosomal related organelles 
in lung cells, by disturbing H+/Ca++ homeostasis (Fois et al., 2015). Therefore, it would be 
interesting to examine approaches for the measurement of lysosomal pH in primary neurons after 
Ambroxol treatment. Another logical investigation would be to assess the expression of regulatory 
biosynthetic and degradative enzymes of gangliosides in neurons treated with Ambroxol.   
     Using LC-ESI-MS, we demonstrated, for the first time, the expression profiles of GM1, GM2 
and GM3 in primary neurons following OGD/R injury. The OGD model was used to investigate 
ganglioside dysregulation previously reported in in vivo models of cerebral ischemia. Thus, 
induction of the cell death by treating the cells with other neurodegenerative agents such as Aß 
oligomers or 1-methyly-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mimic AD and PD 
respectively might provide us with a better understanding of gangliosides behaviour in response 
to various stress conditions. Also, based on the results from the current study and a previous study 
done in neurons (Park et al., 2016), in which GM2 and GM3 showed no significant increase in 
dying neurons, further investigations of ganglioside expression profiles in other brain cells such as 
microglia following OGD stress are warranted. 
     In this study, we also measured cell death following OGD/R injury at 6 h and 24 h after 
reperfusion. Although, there was an increasing trend in cell death following 1 h OGD and 24 h 
reperfusion, this increase showed no statistical significance compared to control neurons. It would 
therefore be interesting to assess cell death after a longer reperfusion time.   
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Section 5: SUMMARY AND CONCLUSIONS 
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Summary of Key Findings 
1. GM1 d18:1 and GM1 d20:1 increased significantly in primary neurons following 
Ambroxol treatment for up to 24 h.  
2. GM2 d18:1 enhanced significantly in primary neurons following Ambroxol treatment. 
3. GM3 d18:1 elevated transiently in primary neurons at 6 h of Ambroxol treatment. 
4. Ambroxol treatment showed no significant increase in cell death in primary cortical rat 
neurons for up to 24 h. 
5. OGD/R injury downregulated GM1, GM2 and GM3 ganglioside expression profiles.  
6. GM1 pretreatment increased cell viability and enhanced GM1 level following OGD/R.  
7. GM1 pretreatment increased GM2 level following OGD at 24 h after reperfusion. 
8. Ambroxol pretreatment recovered GM1 d18:1 at 24 h after reperfusion. 
	
Conclusion 
     In this study, we investigated GM1, GM2 and GM3 ganglioside profile changes following the 
perturbation of their homeostasis by a ganglioside enzyme modifier, Ambroxol. We also assessed 
the neuroprotective effect of Ambroxol following OGD exposure and compared it to neurons 
treated with exogenous GM1. Furthermore, we investigated GM1, GM2, and GM3 ganglioside 
profile changes following OGD/R injury. GM1, GM2 and GM3 increased following Ambroxol 
treatment which was not associated with an increase in cell death. This suggests that the 
neuroprotective effects of GM1 may have been able to counteract the deleterious effects of GM2 
and GM3 accumulation. By assessing cell death following OGD/R injury, Ambroxol pretreatment 
led to no significant increase in cell death following OGD exposure, indicating that Ambroxol may 
protect neurons against OGD/R injury. In addition, there was an increase in cell death in neurons 
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exposed to OGD/R injury, and this increase was not associated with an increase in GM2 and GM3 
levels, suggesting that GM2 and GM3 accumulation in neurons following injury may not be 
essential for neuronal death. Overall, modulating gangliosides by using Ambroxol may provide 
new insights for lipid therapeutic approaches to enhance neuronal survival following brain injury. 
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Figure 23. Mass spectra of GM1 ganglioside from uninjured control neurons. Following the 
detection of gangliosides with a Waters QTOF ESI-MS instrument, chromatogram was extracted 
with Mass Lynx 4.1 to visualize GM1, GM2, GM3 and its d16:1, d18:1, and d20:1 sphingosine 
moieties. Peaks of GM1, GM2 and GM3 are presented relative to each species (A). Higher peaks 
indicate higher quantity of gangliosides. (B) An enlarged spectrum of GM1 d18:1. (C) An enlarged 
spectrum of GM1 d16:1. (D) An enlarged spectrum of GM1 d20:1. 
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Figure 24. Mass spectra of GM2 ganglioside from uninjured control neurons. Following the 
detection of gangliosides with a Waters QTOF ESI-MS instrument, chromatogram was extracted 
with Mass Lynx 4.1 to visualize GM1, GM2, GM3 and its d16:1, d18:1, and d20:1 sphingosine 
moieties. Peaks of GM1, GM2 and GM3 are presented relative to each species. (A) Higher peaks 
indicate higher quantity of gangliosides. (B) Represents an enlarged spectrum of GM2 d16:1, GM2 
d18:1 and GM2 d20:1. 
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Figure 25. Mass spectra of GM3 ganglioside from uninjured control neurons. Following the 
detection of gangliosides with a Waters QTOF ESI-MS instrument, chromatogram was extracted 
from Mass Lynx 4.1 to visualize GM1, GM2, GM3 and its d16:1, d18:1, and d20:1 sphingosine 
moieties. Peaks of GM1, GM2 and GM3 are presented relative to each species (A). Higher peaks 
indicate higher quantity of gangliosides. (B) represents an enlarged spectrum of GM3 d16:1, GM3 
d18:1, and GM3 d20:1. 
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